Monitoring Tumor Response to Antivascular Therapy Using Non-Contrast Intravoxel Incoherent Motion Diffusion-Weighted MRI
Monitoring Tumor Response to Antivascular Therapy Using Non-Contrast Intravoxel Incoherent Motion Diffusion-Weighted MRI
复制标题
DOI：
10.1158/0008-5472.can-16-2499
复制
发表时间：
2017-07-01
期刊：
影响因子：
11.2
通讯作者：
Luo, Liangping
中科院分区：
文献类型：
--
作者：
Shi, Changzheng;Liu, Dexiang;Luo, Liangping
抗血管治疗是非小细胞肺癌（NSCLC）的一种很有前途的治疗方法，其中能够纵向监测治疗反应的成像模式可以提供早期预测结果。在这项研究中，我们试图探讨使用体素内非相干运动（IVIM）扩散MRI定量评估血管破坏剂CA4P或其与贝伐单抗联合治疗实验性NSCLC肿瘤的疗效的可行性。CA4P对肿瘤血管系统有较强但可逆的影响；所有灌注相关参数- D*、f、fD*和k -反式最初在2小时内下降30%至60%，然后在CA4P治疗第2天或CA4P +贝伐单抗治疗第4至8天完全恢复到基线水平；肿瘤内扩散系数在第2 ~ 8天先降低后升高。我们观察到IVIM参数与动态对比增强MRI （DCE-MRI; K-trans）之间存在良好的相关性。我们还发现，2小时f和fD*的相对变化与第8天肿瘤体积的变化具有良好的相关性。总之，我们的研究结果表明，IVIM是一种很有希望的替代DCE-MRI来评估抗血管药物引起的肿瘤灌注变化，并且可以在不需要注射造影剂的情况下预测抗血管治疗的疗效。(c) 2017 aacr。
Antivascular therapy is a promising approach to the treatment of non-small cell lung cancer (NSCLC), where an imaging modality capable of longitudinally monitoring treatment response could provide early prediction of the outcome. In this study, we sought to investigate the feasibility of using intravoxel incoherent motion (IVIM) diffusion MRI to quantitatively assess the efficacy of the treatments of a vascular-disrupting agent CA4P or its combination with bevacizumab on experimental NSCLC tumors. CA4P caused a strong but reversible effect on tumor vasculature; all perfusion-related parameters- D*, f, fD*, and K-trans-initially showed a decrease of 30% to 60% at 2 hours and then fully recovered to baseline on day 2 for CA4P treatment or on days 4 to 8 for CA4P + bevacizumab treatment; the diffusion coefficient in tumors decreased initially at 2 hours and then increased from day 2 to day 8. We observed a good correlation between IVIM parameters and dynamic contrast-enhanced MRI (DCE-MRI; K-trans). We also found that the relative change in f and fD* at 2 hours correlated well with changes in tumor volume on day 8. In conclusion, our results suggest that IVIM is a promising alternative to DCE-MRI for the assessment of the change in tumor perfusion as a result of antivascular agents and can be used to predict the efficacy of antivascular therapies without the need for contrast media injection. (C) 2017 AACR.